Must Read

Bharat Biotech terminates Covaxin deal with Brazil’s Precisa

Bharat's statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country.

By: Reuters | Sao Paulo |
July 23, 2021 5:30:29 pm
Bharat's statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country.

Bharat Biotech has terminated a memorandum of understanding to sell its Covid-19 vaccine Covaxin to Brazil’s Precisa Medicamentos, the Indian company said on Friday without disclosing the reason.

Bharat’s statement said it will continue to work with Brazilian healthcare regulator Anvisa to obtain all required approvals for the use of Covaxin in the country.

There have been allegations in Brazil of irregularities in the government’s efforts to buy 20 million doses of the vaccine using Precisa as an intermediary.

 

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest World News, download Indian Express App.

  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Live Blog

    Best of Express

    Advertisement

    Must Read

    Advertisement

    Buzzing Now

    Advertisement